


### IN THE CLAIMS

The pending unamended claims are reproduced below.


1-13. (CANCELLED)

14. (PREVIOUSLY PRESENTED) A method of treating dyskinesia in a subject comprising administering to the subject a therapeutically effective amount of a compound of the formula (I):



wherein X is Oxygen or  $\text{CH}_2$ ;

$\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$ ,  $\text{R}_4$  and  $\text{R}_5$  are independently Hydrogen, lower alkyl and  $\text{R}_2$  and  $\text{R}_3$  and/or  $\text{R}_4$  and  $\text{R}_5$  together may be a group of the formula (II):



wherein  $\text{R}_6$  and  $\text{R}_7$  are the same or different and are Hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring, wherein the dyskinesia is manifest as chorea or dystonia.

15. (PREVIOUSLY PRESENTED) The method of claim 14, wherein the compound is topiramate.

16-18. (CANCELLED)

19. (PREVIOUSLY PRESENTED) The method of claim 14 or 27, wherein the dyskinesia is associated with dopamine replacement therapy.

20-24. (CANCELLED).

25. (PREVIOUSLY PRESENTED) The method of claim 14 or 27, wherein the dyskinesia arises as a side-effect of the treatment of parkinsonism with a therapeutic agent.

26. (PREVIOUSLY PRESENTED) The method of claim 25, wherein the therapeutic agent is selected from the group consisting of ropinirole, pramipexole, cabergoline, bromocriptine, lisuride, pergolide, L-DOPA and apomorphine.

27. (PREVIOUSLY PRESENTED) The method of claim 14, wherein the dyskinesia arises as a side-effect of a therapeutic agent.